Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pear Therapeutics Inc.

www.peartherapeutics.com

Latest From Pear Therapeutics Inc.

Novartis Q3 Preview: Zolgensma Back In The Spotlight

Analysts will be keen to hear about the launches of key new drugs Zolgensma and Mayzent as they ponder how long sales of Cosentyx can keep climbing.

Sales & Earnings Commercial

Sandoz Breaks Off Digital Deal With Pear

Sandoz has announced that partner Pear Therapeutics will now market alone the reSET and reSET-O digital therapeutics launched by the pair in the US almost a year ago. The move follows Richard Saynor taking charge of Sandoz as part of the Novartis unit’s current transformation.

Strategy Digital Health

Value Added Medicines Hold Promise Despite Challenges

An IQVIA report dives into how technology can facilitate a digital future for value added medicines, while discussing the market size, opportunities, scope of growth and challenges for this emerging sector in healthcare.

Value-Added Medicines Market Intelligence

NESTcc Test Case List Includes Apple Watch, Pelvic Mesh

The National Evaluation System for health Technology Coordinating Center announced 12 new test cases that use real-world evidence to examine medical device industry priorities. The list includes an Apple Watch study, as well as an FDA proposal on the use of pelvic mesh to treat urinary incontinence.

Health Technology Assessment Review Pathway
See All

Company Information

  • Industry
  • Digital Health
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pear Therapeutics Inc.
  • Senior Management
  • Guiffre Christopher, CFO & CEO
    Alex Waldron, Chief Commercial Officer
    Ian McFarland, General Mgr. & CTO
    Yuri Maricich , MD, Acting CMO & Head, Clinical Dev.
  • Contact Info
  • Pear Therapeutics Inc.
    745 Atlantic Ave.
    Boston, MA 02111
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register